Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network

References

• Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe. 2016;40:95–99. doi:10.1016/j.anaerobe.2016.06.008
   PubMed Web of Science ®Google Scholar
• Cho JM, Pardi DS, Khanna S. Update on treatment of Clostridioides difficile infection. Mayo Clin Proc. 2020;95(4):758–769. doi:10.1016/j.mayocp.2019.08.006
   PubMed Web of Science ®Google Scholar
• Fettucciari K, Marconi P, Marchegiani A, Fruganti A, Spaterna A, Bassotti G. Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile. Therap Adv Gastroenterol. 2021;14:175628482110327. doi:10.1177/17562848211032797
   Web of Science ®Google Scholar
• Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211–1221. doi:10.1007/s10096-019-03539-6
   PubMed Web of Science ®Google Scholar
• Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol. 2021;14:1–11. doi:10.1177/17562848211009694
   Web of Science ®Google Scholar
• Shafiq M, Alturkmani H, Zafar Y, et al. Effects of co-infection on the clinical outcomes of Clostridium difficile infection. Gut Pathog. 2020;12(1). doi:10.1186/s13099-020-00348-7
   PubMed Web of Science ®Google Scholar
• Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S. Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo). 2014;2014:1–9. doi:10.1155/2014/916826
   Google Scholar
• Fettucciari K, Fruganti A, Marchegiani A, Brancorsini S, Marconi P, Bassotti G. Proinflammatory cytokines: possible accomplices for the systemic effects of Clostridioides difficile toxin b. J Inflamm Res. 2021;14:57–62. doi:10.2147/JIR.S287096
   PubMed Web of Science ®Google Scholar
• Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, Di Masi A. Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel). 2016;8(5):134. doi:10.3390/toxins8050134
   PubMed Web of Science ®Google Scholar
• Kochan TJ, Foley MH, Shoshiev MS, Somers MJ, Carlson PE, Hanna PC. Updates to Clostridium difficile spore germination. J Bacteriol. 2018;200(16):1–12. doi:10.1128/JB.00218-18
   Web of Science ®Google Scholar
• Shen A. Clostridioides difficile spore formation and germination: new insights and opportunities for intervention. Annu Rev Microbiol. 2020;74(1):545–566. doi:10.1146/annurev-micro-011320-011321
   PubMedGoogle Scholar
• Castro-Córdova P, Mora-Uribe P, Reyes-Ramírez R, et al. Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection. Nat Commun. 2021;12. doi:10.1038/s41467-021-21355-5
   PubMed Web of Science ®Google Scholar
• Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63(2):193–202. doi:10.1016/j.molimm.2014.09.005
   PubMed Web of Science ®Google Scholar
• Oliva A, Aversano L, de Angelis M, et al. Persistent systemic microbial translocation, inflammation, and intestinal damage during Clostridioides difficile infection. Open Forum Infect Dis. 2020;7(1). doi:10.1093/ofid/ofz507
   Web of Science ®Google Scholar
• Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol. 2021;37(4):336–343. doi:10.1097/MOG.0000000000000739
   PubMed Web of Science ®Google Scholar
• Zhang T, Lin QY, Fei JX, et al. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep. 2016;6:1–9. doi:10.1038/srep29791
   PubMed Web of Science ®Google Scholar
• Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021;19(3):265–274. doi:10.5217/ir.2020.00045
   PubMed Web of Science ®Google Scholar
• Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723–750. doi:10.1093/femsre/fux048
   PubMed Web of Science ®Google Scholar
• Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel). 2010;2(7):1848–1880. doi:10.3390/toxins2071848
   PubMed Web of Science ®Google Scholar
• Aktories K, Schwan C, Jank T. Clostridium difficile toxin biology. Annu Rev Microbiol. 2017;71(1):281–307. doi:10.1146/annurev-micro-090816-093458
   PubMed Web of Science ®Google Scholar
• Pruitt RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol. 2012;2:28. doi:10.3389/fcimb.2012.00028
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Taminiau B, Van Broeck J, Delmée M, Daube G. Clostridium difficile infection and intestinal microbiota interactions. Microb Pathog. 2015;89:201–209. doi:10.1016/j.micpath.2015.10.018
   PubMed Web of Science ®Google Scholar
• Darkoh C, Plants-Paris K, Bishoff D, DuPont HL. Clostridium difficile modulates the gut microbiota by inducing the production of indole, an interkingdom signaling and antimicrobial molecule. mSystems. 2019;4(2). doi:10.1128/msystems.00346-18
   PubMed Web of Science ®Google Scholar
• Rodríguez C, Romero E, Garrido-Sanchez L, et al. Microbiota insights in Clostridium difficile infection and inflammatory bowel disease. Gut Microbes. 2020;12(1):1725220. doi:10.1080/19490976.2020.1725220
   PubMed Web of Science ®Google Scholar
• Fettucciari K, Ponsini P, Gioè D, et al. Enteric glial cells are susceptible to Clostridium difficile toxin B. Cell Mol Life Sci. 2017;74(8):1527–1551. doi:10.1007/s00018-016-2426-4
   PubMed Web of Science ®Google Scholar
• Macchioni L, Davidescu M, Fettucciari K, et al. Enteric glial cells counteract Clostridium difficile toxin B through a NADPH oxidase/ROS/JNK/caspase-3 axis, without involving mitochondrial pathways. Sci Rep. 2017;7. doi:10.1038/srep45569
   Web of Science ®Google Scholar
• Fettucciari K, Macchioni L, Davidescu M, et al. Clostridium difficile toxin B induces senescence in enteric glial cells: a potential new mechanism of Clostridium difficile pathogenesis. Biochim Biophys Acta. 2018;1865(12):1945–1958. doi:10.1016/j.bbamcr.2018.10.007
   Web of Science ®Google Scholar
• Bassotti G, Macchioni L, Corazzi L, Marconi P, Fettucciari K. Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum? Cell Mol Life Sci. 2018;75(7):1145–1149. doi:10.1007/s00018-017-2736-1
   PubMed Web of Science ®Google Scholar
• Bassotti G, Marchegiani A, Marconi P, Fettucciari K. The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses. Microbiologyopen. 2020;9(8). doi:10.1002/mbo3.1061
   PubMed Web of Science ®Google Scholar
• Bloomfield LE, Riley TV. Epidemiology and risk factors for community-associated Clostridium difficile infection: a narrative review. Infect Dis Ther. 2016;5(3):231–251. doi:10.1007/s40121-016-0117-y
   PubMedGoogle Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2014;8(6):443–468. doi:10.1016/j.crohns.2013.12.013
   Google Scholar
• Antonelli E, Baldoni M, Giovenali P, Villanacci V, Essatari M, Bassotti G. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohn's Colitis. 2012;6:154–159. doi:10.1016/j.crohns.2011.07.012
   Google Scholar
• Chen XL, Deng J, Chen X, Wan SS, Wang Y, Cao Q. High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: a prospective observational cohort study. J Dig Dis. 2019;20(9):460–466. doi:10.1111/1751-2980.12798
   PubMed Web of Science ®Google Scholar
• Zhou F, Hamza T, Fleur AS, et al. Mice with inflammatory bowel disease are susceptible to Clostridium difficile infection with severe disease outcomes. Inflamm Bowel Dis. 2018;24(3):573–582. doi:10.1093/ibd/izx059
   PubMed Web of Science ®Google Scholar
• Flegel WA, Muller F, Daubener W, Fischer HG, Hadding U, Northoff H. Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun. 1991;59(10):3659–3666. doi:10.1128/iai.59.10.3659-3666.1991
   PubMed Web of Science ®Google Scholar
• Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14(10):609–620. doi:10.1038/nrmicro.2016.108
   PubMed Web of Science ®Google Scholar
• Wu X, Lai X, Tu H, Zou H, Cao J. Elevated serum CXCL10 in patients with Clostridium difficile infection are associated with disease severity. Int Immunopharmacol. 2019;72:92–97. doi:10.1016/j.intimp.2019.03.033
   PubMed Web of Science ®Google Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–337. doi:10.1038/s41575-020-0273-0
   PubMed Web of Science ®Google Scholar
• Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases – update 2020. Pharmacol Res. 2020;158:104835. doi:10.1016/j.phrs.2020.104835
   PubMed Web of Science ®Google Scholar
• Villanacci V, Cadei M, Lanzarotto F, et al. Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Ann Diagn Pathol. 2019;38:20–25. doi:10.1016/j.anndiagpath.2018.10.011
   PubMed Web of Science ®Google Scholar
• Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16(10):1277–1290. doi:10.1080/14712598.2016.1203897
   PubMed Web of Science ®Google Scholar
• Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: local tumor necrosis factor-α inhibition in inflammatory bowel disease. Pharmaceutics. 2020;12(6):1–31. doi:10.3390/pharmaceutics12060539
   Web of Science ®Google Scholar
• Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767.e1. doi:10.1053/j.gastro.2011.02.016
   PubMed Web of Science ®Google Scholar
• Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016;7(3):353. doi:10.4292/wjgpt.v7.i3.353
   PubMedGoogle Scholar
• Bassotti G, Villanacci V, Antonelli E, Morelli A, Salerni B. Enteric glial cells: new players in gastrointestinal motility? Lab Investig. 2007;87(7):628–632. doi:10.1038/labinvest.3700564
   PubMed Web of Science ®Google Scholar
• Grubišić V, Gulbransen BD. Enteric glia: the most alimentary of all glia. J Physiol. 2017;595(2):557–570. doi:10.1113/JP271021
   PubMed Web of Science ®Google Scholar
• Cabarrocas J, Savidge TC, Liblau RS. Role of enteric glial cells in inflammatory bowel disease. Glia. 2003;41(1):81–93. doi:10.1002/glia.10169
   PubMed Web of Science ®Google Scholar
• Bassotti G, Villanacci V, Nascimbeni R, et al. Enteric neuroglial apoptosis in inflammatory bowel diseases. J Crohn's Colitis. 2009;3(4):264–270. doi:10.1016/j.crohns.2009.06.004
   Google Scholar
• Capoccia E, Cirillo C, Gigli S, et al. Enteric glia: a new player in inflammatory bowel diseases. Int J Immunopathol Pharmacol. 2015;28(4):443–451. doi:10.1177/0394632015599707
   PubMed Web of Science ®Google Scholar
• Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil. 2008;20(9):1009–1016. doi:10.1111/j.1365-2982.2008.01146.x
   PubMed Web of Science ®Google Scholar
• Kermarrec L, Durand T, Neunlist M, Naveilhan P, Neveu I. Enteric glial cells have specific immunosuppressive properties. J Neuroimmunol. 2016;295–296:79–83. doi:10.1016/j.jneuroim.2016.04.011
   PubMed Web of Science ®Google Scholar
• Pochard C, Coquenlorge S, Freyssinet M, et al. The multiple faces of inflammatory enteric glial cells: is crohn’s disease a gliopathy? Am J Physiol. 2018;315(1):G1–G11. doi:10.1152/ajpgi.00016.2018
   Google Scholar
• Fitzgibbon G, Mills KHG. The microbiota and immune-mediated diseases: opportunities for therapeutic intervention. Eur J Immunol. 2020;50(3):326–337. doi:10.1002/eji.201948322
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol. 2013;19(43):7577–7585. doi:10.3748/wjg.v19.i43.7577
   PubMed Web of Science ®Google Scholar
• Belkind-Gerson J, Graham HK, Reynolds J, et al. Colitis promotes neuronal differentiation of Sox2+ and PLP1+ enteric cells. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-02890-y
   PubMedGoogle Scholar
• Abhyankar MM, Ma JZ, Scully KW, et al. Immune profiling to predict outcome of Clostridioides difficile infection. MBio. 2020;11(3). doi:10.1128/mBio.00905-20
   PubMed Web of Science ®Google Scholar
• Dieterle MG, Putler R, Perry DA, et al. Systemic inflammatory mediators are effective biomarkers for predicting adverse outcomes in Clostridioides difficile infection. MBio. 2020;11(3). doi:10.1128/mBio.00180-20
   PubMed Web of Science ®Google Scholar
• Koon HW, Wang J, Mussatto CC, et al. Fidaxomicin and OP-1118 inhibit Clostridium difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity. Antimicrob Agents Chemother. 2018;62(1). doi:10.1128/AAC.01513-17
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–431. doi:10.1056/nejmoa0910812
   PubMed Web of Science ®Google Scholar
• Spiceland CM, Khanna S, Pardi DS. Outcomes with fidaxomicin therapy in Clostridium difficile infection. J Clin Gastroenterol. 2018;52(2):151–154. doi:10.1097/MCG.0000000000000769
   PubMed Web of Science ®Google Scholar
• Qiu H, Sun X, Sun M, He C, Li Z, Liu Z. Serum bacterial toxins are related to the progression of inflammatory bowel disease. Scand J Gastroenterol. 2014;49(7):826–833. doi:10.3109/00365521.2014.919018
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–264. doi:10.1111/j.1365-2036.2009.04037.x
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Oxford EC, Nguyen DD, Sauk J, Yajnik V, Xavier RJ. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol Ther. 2013;38(5):522–530. doi:10.1111/apt.12425
   PubMed Web of Science ®Google Scholar
• Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45(12):969–977. doi:10.1016/j.dld.2013.06.010
   PubMedGoogle Scholar
• Gholam-Mostafaei FS, Yadegar A, Aghdaei HA, Azimirad M, Daryani NE, Zali MR. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease. Curr Res Transl Med. 2020;68:125–130. doi:10.1016/j.retram.2020.03.002
   PubMed Web of Science ®Google Scholar
• Seicean A, Moldovan-Pop A, Seicean R. Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab. World J Gastroenterol. 2014;20(17):5135–5140. doi:10.3748/wjg.v20.i17.5135
   PubMed Web of Science ®Google Scholar